Virpath is a laboratory specialized in the study of respiratory viruse.
It is important to note that respiratory viruses have considerable potential for rapid spread throughout the world, which imposes an urgent need for new rapid response strategies for effective containment and control. There is an ongoing need for a better understanding of their evolution and functional impact on the host.
Virpath proposes an integrative approach to analyze the epidemiology, impact, pathogenesis, characterization and control of emerging and re-emerging respiratory viruses. Our laboratory works on different aspects of respiratory virus biology, from the decryption of the mechanisms leading to the emergence and pathogenesis of influenza virus, analysis of viral interactions with key host cells and factors during respiratory viral infection.
We are also interested in antiviral resistance mechanisms, as well as the discovery of innovative antiviral strategies targeting the host (drug reuse) and optimizing the quality and potency of vaccines as new ways to fight influenza and pneumovirus infections.
To this end, our laboratory has implemented new technical skills, including reverse genetics, transcriptomic analysis of clinical samples and a fully functional vaccine antigen production and characterization platform.
A technology research platform (VirNext ) has been developed to improve translational research and stimulate partnerships and technology transfer to industry.